Advertisement
U.S. markets closed
Advertisement

Virax Biolabs Group Limited (VRAX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
0.2103-0.0222 (-9.55%)
At close: 03:59PM EST
0.2170 +0.01 (+3.19%)
After hours: 07:37PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Symmetrical Continuation Triangle (Bearish)

Symmetrical Continuation Triangle (Bearish)

Performance Outlook
Previous Close0.2325
Open0.2320
Bid0.2096 x 1100
Ask0.2170 x 2200
Day's Range0.1804 - 0.2320
52 Week Range0.1800 - 1.6000
Volume380,227
Avg. Volume166,911
Market Cap3.762M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.5100
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for VRAX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Virax Biolabs Group Limited
    Daily – Vickers Top Insider Picks for 03/13/2023The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    9 months agoArgus Research
View more
  • Zacks Small Cap Research

    VRAX: Virax Biolabs transformative preventive diagnostic platform supports higher stock price.

    By Thomas Kerr, CFA NASDAQ:VRAX READ THE FULL VRAX RESEARCH REPORT On September 12, 2023, Virax Biolabs (NASDAQ:VRAX) announced the launch of an early access program for research-use-only ("RUO") of its proprietary SARS-Cov-2 ViraxImmune T-cell-based test. The early access program offers select research groups an opportunity to be at the forefront of immune assessment advancements. The RUO form

  • PR Newswire

    Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar

    Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced today the launch of an early access program for the research-use-only ("RUO") of its proprietary SARS-Cov-2 ViraxImmune T-cell-based test. The company will host a webinar on September 20, 2023 at 10 AM EST.

  • PR Newswire

    Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum

    Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced today the appointment of Dr. Nigel McCracken as the Company's Chief Operating Officer ("COO"). Dr. McCracken will succeed Mr. Cameron Shaw, who is moving to Virax's Advisory Board, and will lead the Company's various growth initiatives, including the Company's expected near-term research-use-only launch of